J. S. Duncan

This study identifies CDK9 as a novel therapeutic target in RAC1P29S-mutant melanoma and shows that combining CDK9 inhibition with anti-PD-1 therapy enhances tumor suppression.

This study identifies MDR1 as a mediator of resistance to PROTACs in cancer cells and shows that combining MDR1 inhibitors with PROTACs enhances drug efficacy.

This study identifies NetrinG1+ cancer-associated fibroblasts that produce extracellular vesicles supporting pancreatic cancer cell survival under nutrient stress.

This study uses MIB-MS to compare kinase profiles between newly diagnosed and recurrent glioblastoma, identifying differences in signaling pathways associated with tumor recurrence.

This study shows that inactivating Pak2 reduces tumor development in Nf2-deficient mice, suggesting PAK inhibition could be a therapeutic strategy for NF2-deficient cancers.

The paper develops a SILAC-based MIB-MS workflow to profile the kinome in endometrial tumors, identifying SRPK1 as a potential therapeutic target.